Christer Borgfeldt

List of Publications by Year
in descending order

71 papers	1,754 citations	304743 22 h-index	302126 39 g-index
72 all docs	72 docs citations	72 times ranked	2357 citing authors

#	ARTICLE	IF	CITATIONS
1	The wait time to primary surgery in endometrial cancer â€" impact on survival and predictive factors: a population-based SweGCG study. Acta OncolÃ³gica, 2022, 61, 30-37.	1.8	0
2	Coâ€testing in cervical screening among 40â€to 42â€yearâ€old women is unreasonable. Acta Obstetricia Et Gynecologica Scandinavica, 2022, 101, 374-378.	2.8	5
3	Circulating Markers of Neutrophil Extracellular Traps (NETs) in Patients With Ovarian Tumors. Anticancer Research, 2022, 42, 965-971.	1.1	4
4	The association between common urogenital infections and cervical neoplasia â€" A nationwide cohort study of over four million women (2002â€"2018). Lancet Regional Health - Europe, The, 2022, 17, 100378.	5.6	1
5	Time Trends for Incidence and Net Survival of Cervical Cancer in Sweden 1960â€"2014â€"A Nationwide Population-Based Study. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1572-1581.	2.5	4
6	Areas to Improve Quality of Life After Ovarian Tumor Surgery and Adjuvant Treatment. In Vivo, 2021, 35, 2399-2408.	1.3	2
7	Promotion of Cervical Screening among Long-term Non-attendees by Human Papillomavirus Self-sampling. Journal of Cancer Prevention, 2021, 26, 25-31.	2.0	5
8	Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG study. Gynecologic Oncology, 2021, 161, 244-250.	1.4	6
9	Incidence and survival of epithelial ovarian, fallopian tube, peritoneal, and undesignated abdominal/pelvic cancers in Sweden 1960â€"2014: A population-based cohort study. BMC Cancer, 2021, 21, 465.	2.6	1
10	<scp>HPV73</scp> in cervical cancer and distribution of <scp>HPV73</scp> variants in cervical dysplasia. International Journal of Cancer, 2021, 149, 936-943.	5.1	4
11	Equal prevalence of severe cervical dysplasia by HPV self-sampling and by midwife-collected samples for primary HPV screening: a randomised controlled trial. European Journal of Cancer Prevention, 2021, 30, 334-340.	1.3	8
12	Preoperative and intraoperative assessment of myometrial invasion in endometrial cancerâ€"A Swedish Gynecologic Cancer Group (SweGCG) study. Acta Obstetricia Et Gynecologica Scandinavica, 2021, 100, 1526-1533.	2.8	16
13	Survival in endometrial cancer in relation to minimally invasive surgery or open surgery â€" a Swedish Gynecologic Cancer Group (SweGCG) study. BMC Cancer, 2021, 21, 658.	2.6	2
14	Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II. Journal of Clinical Oncology, 2021, 39, 3623-3632.	1.6	69
15	Negative Pressure Wound Therapy (NPWT) in Groin Wounds After Lymphadenectomy in Vulvar Cancer Patients. In Vivo, 2020, 34, 3511-3517.	1.3	1
16	14-type HPV mRNA test in triage of HPV DNA-positive postmenopausal women with normal cytology. BMC Cancer, 2020, 20, 1025.	2.6	4
17	Primary treatment and relative survival by stage and age in vulvar squamous cell carcinoma: A population-based SweGCG study. Gynecologic Oncology, 2020, 159, 663-671.	1.4	10
18	Cervical cancer prevention among long-term screening non-attendees by vaginal self-collected samples for hr-HPV mRNA detection. Infectious Agents and Cancer, 2020, 15, 10.	2.6	15

#	Article	IF	Citations
19	Detection of HPV mRNA in Self-collected Vaginal Samples Among Urban Ethiopian Women. Anticancer Research, 2020, 40, 1513-1517.	1.1	1
20	A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients. PLoS ONE, 2020, 15, e0240418.	2.5	15
21	Lymphovascular space invasion as a predictive factor for lymph node metastases and survival in endometrioid endometrial cancer â€" a Swedish Gynecologic Cancer Group (SweGCG) study. Acta OncolÃ³gica, 2019, 58, 1628-1633.	1.8	55
22	Primary treatment patterns and survival of cervical cancer in Sweden: A population-based Swedish Gynecologic Cancer Group Study. Gynecologic Oncology, 2019, 155, 229-236.	1.4	12
23	Primary screening for increased fracture risk by the FRAXÂ® questionnaireâ€"uptake rates in relation to invitation method. Archives of Osteoporosis, 2019, 14, 51.	2.4	3
24	Population-based primary HPV mRNA cervical screening compared with cytology screening. Preventive Medicine, 2019, 124, 61-66.	3.4	11
25	Increased HPV detection by the use of a pre-heating step on vaginal self-samples analysed by Aptima HPV assay. Journal of Virological Methods, 2019, 270, 18-20.	2.1	8
26	Detection of HPV mRNA in Self-collected Vaginal Samples Among Women at 69-70 Years of Age. Anticancer Research, 2019, 39, 381-386.	1.1	8
27	Confounders other than comorbidity explain survival differences in Danish and Swedish ovarian cancer patients â€" a comparative cohort study. Acta OncolÃ³gica, 2018, 57, 1100-1108.	1.8	6
28	Self-sampling with HPV mRNA analyses from vagina and urine compared with cervical samples. Journal of Clinical Virology, 2018, 101, 69-73.	3.1	38
29	A Swedish population-based evaluation of benign hysterectomy, comparing minimally invasive and abdominal surgery. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 222, 113-118.	1.1	25
30	Lymph node metastases as only qualifier for stage IV serous ovarian cancer confers longer survival than other sites of distant disease â€" a Swedish Gynecologic Cancer Group (SweGCG) study. Acta OncolÃ³gica, 2018, 57, 331-337.	1.8	17
31	Data quality in the Swedish Quality Register of Gynecologic Cancer â€" a Swedish Gynecologic Cancer Group (SweGCG) study. Acta OncolÃ³gica, 2018, 57, 346-353.	1.8	41
32	Prevalence of High-risk HPV in Postmenopausal Women with Benign Cervical Cytology â€" A Population-based Cohort Study. Anticancer Research, 2018, 38, 4221-4228.	1.1	8
33	Risk factors for lymph node metastases in women with endometrial cancer: A populationâ€based, nationâ€wide register studyâ€"On behalf of the Swedish Gynecological Cancer Group. International Journal of Cancer, 2017, 140, 2693-2700.	5.1	23
34	Increased blood cadmium levels were not associated with increased fracture risk but with increased total mortality in women: the MalmÃ¶ Diet and Cancer Study. Osteoporosis International, 2017, 28, 2401-2408.	3.1	21
35	Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG). Gynecologic Oncology, 2017, 144, 167-173.	1.4	23
36	Postmenopausal hormone therapy and risk of stroke: A pooled analysis of data from population-based cohort studies. PLoS Medicine, 2017, 14, e1002445.	8.4	44

#	ARTICLE	IF	CITATIONS
37	The economic burden of human papillomavirus-related precancers and cancers in Sweden. PLoS ONE, 2017, 12, e0179520.	2.5	16
38	Ovarian Cancer Surgery â€" A Population-based Registry Study. Anticancer Research, 2017, 37, 1837-1845.	1.1	9
39	Vaginal and Urine Self-sampling Compared to Cervical Sampling for HPV-testing with the Cobas 4800 HPV Test. Anticancer Research, 2017, 37, 4183-4187.	1.1	18
40	A populationâ€based registry study evaluating surgery in newly diagnosed uterine cancer. Acta Obstetricia Et Gynecologica Scandinavica, 2016, 95, 901-911.	2.8	17
41	HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia. British Journal of Cancer, 2016, 115, 725-730.	6.4	12
42	Follow up with <scp>HPV</scp> test and cytology as test of cure, 6Âmonths after conization, is reliable. Acta Obstetricia Et Gynecologica Scandinavica, 2016, 95, 1251-1257.	2.8	21
43	Longâ€term survival in women with borderline ovarian tumors: a populationâ€based survey of borderline ovarian tumors in Sweden 1960â€"2007. Acta Obstetricia Et Gynecologica Scandinavica, 2016, 95, 473-479.	2.8	17
44	A Biomarker Panel Increases the Diagnostic Performance for Epithelial Ovarian Cancer Type I and II in Young Women. Anticancer Research, 2016, 36, 957-65.	1.1	16
45	A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer â€" An international multicenter study in women with an ovarian mass. Gynecologic Oncology, 2015, 138, 640-646.	1.4	78
46	Robotâ€assisted surgery in cervical cancer patients reduces the time to normal activities of daily living. Acta Obstetricia Et Gynecologica Scandinavica, 2015, 94, 260-265.	2.8	21
47	A population-based study of pelvic serous carcinoma in Sweden: Primary site, FIGO stage and survival.. Journal of Clinical Oncology, 2015, 33, e16533-e16533.	1.6	0
48	Age influences the clinical significance of atypical glandular cells on cytology. Anticancer Research, 2015, 35, 913-9.	1.1	9
49	Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study. Maturitas, 2014, 78, 310-315.	2.4	43
50	Elderly women above screening age diagnosed with cervical cancer have a worse prognosis. Anticancer Research, 2014, 34, 5147-51.	1.1	29
51	Low androstenedione/sex hormone binding globulin ratio increases fracture risk in postmenopausal women. The Women's Health in the Lund Area study. Maturitas, 2013, 75, 270-275.	2.4	9
52	Comparison of use of vaginal HPV self-sampling and offering flexible appointments as strategies to reach long-term non-attending women in organized cervical screening. Journal of Clinical Virology, 2013, 58, 155-160.	3.1	54
53	Vaginal self-sampling without preservative for human papillomavirus testing shows good sensitivity. Journal of Clinical Virology, 2013, 56, 52-56.	3.1	21
54	Reproducibility and accuracy of robot-assisted laparoscopic fertility sparing radical trachelectomy. Gynecologic Oncology, 2012, 127, 484-488.	1.4	67

#	Article	IF	Citations
55	High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer. Journal of Ovarian Research, 2012, 5, 20.	3.0	48
56	Robot-assisted removal of a lymphocyst causing severe neuralgic pain and adductor atrophy. Journal of Robotic Surgery, 2011, 5, 299-302.	1.8	0
57	The sentinel node concept in early cervical cancer performs well in tumors smaller than 2Âcm. Gynecologic Oncology, 2010, 117, 266-269.	1.4	75
58	Robot assisted laparoscopic radical hysterectomy and pelvic lymphadenectomy with short and long term morbidity data. Gynecologic Oncology, 2009, 113, 185-190.	1.4	100
59	Cleaved Forms of the Urokinase Plasminogen Activator Receptor in Plasma Have Diagnostic Potential and Predict Postoperative Survival in Patients with Ovarian Cancer. Clinical Cancer Research, 2008, 14, 5785-5793.	7.0	67
60	Fertility-sparing surgery and outcome in fertile women with ovarian borderline tumors and epithelial invasive ovarian cancer. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2007, 134, 110-114.	1.1	56
61	Background factors influencing somatic and psychological symptoms in middle-age women with different hormonal status. Maturitas, 2005, 52, 306-318.	2.4	38
62	Cancer risk after hospital discharge diagnosis of benign ovarian cysts and endometriosis. Acta Obstetricia Et Gynecologica Scandinavica, 2004, 83, 395-400.	2.8	115
63	Low-dose oral combination of 17Î²-estradiol and norethisterone acetate in postmenopausal women decreases factor VII, fibrinogen, antithrombin and plasminogen activator inhibitor-1. Climacteric, 2004, 7, 78-85.	2.4	19
64	Menopause-related symptoms: What are the background factors? A prospective population-based cohort study of Swedish women (The Women's Health in Lund Area study). American Journal of Obstetrics and Gynecology, 2003, 189, 1646-1653.	1.3	113
65	High preoperative plasma concentration of tissue plasminogen activator (tPA) is an independent marker for shorter overall survival in patients with ovarian cancer. Gynecologic Oncology, 2003, 91, 112-117.	1.4	12
66	High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer. International Journal of Cancer, 2003, 107, 658-665.	5.1	16
67	Low-dose hormone therapy and carbohydrate metabolism. Fertility and Sterility, 2003, 79, 550-555.	1.0	32
68	Changes in lipid and lipoprotein profile in postmenopausal women receiving low-dose combinations of 17??-estradiol and norethisterone acetate. Menopause, 2002, 9, 335-342.	2.0	20
69	Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1). International Journal of Cancer, 2001, 92, 497-502.	5.1	45
70	High tissue content of urokinase plasminogen activator (u-PA) is associated with high stromal expression of u-PA mRNA in poorly differentiated serous ovarian carcinoma. International Journal of Cancer, 1998, 79, 588-595.	5.1	20
71	Longâ€term incidence of endometrial cancer after endometrial resection and ablation: A population based Swedish gynecologic cancer group (<scp>SweGCG</scp>) study. Acta Obstetricia Et Gynecologica Scandinavica, 0, , .	2.8	4